Detailed price information for Prime Medicine Inc (PRME-Q) from The Globe and Mail including charting and trades.

Prime Medicine, Inc. (NASDAQ:PRME) stated on December 7, 2025, that the New England Journal of Medicine has published Phase 1/2 clinical results for PM359, its experimental autologous hematopoietic ...

Prime Medicines PRME has made encouraging pipeline progress of late and investors will focus on related updates when it reports second-quarter 2024 results next month. The Zacks Consensus Estimate for ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Prime Medicine, Inc.’s PRME shares have risen 16.4% in the past three months compared with the industry’s growth of 10.9%. The stock has also outperformed the sector and the S&P 500. The encouraging ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other CRISPR stocks.

Short interest in Prime Medicine Inc (NASDAQ:PRME) decreased during the last reporting period, falling from 19.25M to 19.12M. This put 17.63% of the company's publicly available shares short. Short ...

We recently compiled a list of the 10 Most Shorted Stocks That Are Loved by Analysts. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other ...